A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
NCT05669430
This study is recruiting at 10 US sites in 9 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Solid Tumor, Adult
- Refractory Cancer
- Endometrial Carcinoma (EC)
- Squamous Head and Neck Carcinoma
- pMMR/MSS Adenocarcinoma of the Colon or Rectum
- Cutaneous Melanoma
- Non-Small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- GV20 Therapeutics
- Last updated on ClinicalTrials.gov
- February 13, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- The Angeles Clinic and Research Institute · Los Angeles, CA
Connecticut · 1
- Yale University · New Haven, CT
Indiana · 1
- Community Health Network, Inc. · Indianapolis, IN
Massachusetts · 1
- Massachusetts General Hospital · Boston, MA
Michigan · 1
- Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center · Detroit, MI
New York · 1
- NYU Langone Health · New York, NY
Oregon · 1
- Oregon Health & Science University · Portland, OR
Texas · 2
- Oncology Consultants, P.A. · Houston, TX
- The University of Texas M. D. Anderson Cancer Center · Houston, TX
Virginia · 1
- Virginia Cancer Specialists · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.